Towards targeting anticancer drugs: ruthenium(ii)–arene complexes with biologically active naphthoquinone-derived ligand systems
- 6 May 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 45 (33) , 13091-13103
Abstract
2-Hydroxy-[1,4]-naphthoquinone-derived ligands and their RuII(η6-p-cymene)Cl complexes were prepared with the aim to obtain multimodal anticancer agents.Keywords
This publication has 53 references indexed in Scilit:
- Metal–Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular AccumulationOrganometallics, 2013
- ShelXle: a Qt graphical user interface forSHELXLJournal of Applied Crystallography, 2011
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsCancers, 2011
- OLEX2: a complete structure solution, refinement and analysis programJournal of Applied Crystallography, 2009
- A short history of SHELXActa Crystallographica Section A Foundations of Crystallography, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Redox behavior of tumor-inhibiting ruthenium(iii) complexes and effects of physiological reductants on their binding to GMPDalton Transactions, 2006
- An Easy Approach to Prepare Naphtho [−2, 3-b] Furan-4, 9-dionesSynthetic Communications, 1989
- Naphthoquinone Antimalarials. IV-XI. Synthesis1Journal of the American Chemical Society, 1948